Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Update

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 56,514 shares, a growth of 172.7% from the August 15th total of 20,724 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 950,731 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Evaxion A/S

Several hedge funds have recently modified their holdings of EVAX. Renaissance Technologies LLC bought a new position in Evaxion A/S during the first quarter valued at $146,000. SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S in the 4th quarter valued at about $72,000. Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S during the fourth quarter worth approximately $38,000. Rathbones Group PLC purchased a new stake in Evaxion A/S during the first quarter valued at approximately $170,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Evaxion A/S during the first quarter valued at approximately $112,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Evaxion A/S Trading Up 1.0%

EVAX stock opened at $3.13 on Friday. Evaxion A/S has a 1-year low of $2.77 and a 1-year high of $12.15. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. The company has a market capitalization of $26.10 million, a price-to-earnings ratio of -2.59 and a beta of 0.26. The business has a 50 day simple moving average of $3.09 and a two-hundred day simple moving average of $3.54.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.